Skip to main content
. 2022 May 2;22:143. doi: 10.1186/s12905-022-01726-w

Table 2.

Demographic and clinical characteristics of 152 patients

Variables Patients (n = 152)
Age, mean (SD) [range], years 32 (4) [22–48]
BMI (kg/m2)
 ≥ 30 8 (5.3%)
25–30 64 (42.1%)
18.5–24.99 71 (46.7%)
< 18.5 9 (5.9%)
Time interval between birth and onset of GLM (years)
Pregnancy 15 (9.9%)
Breastfeeding 4 (2.6%)
Time until last birth (years) (< 2, no breastfeeding) 26 (17.1%)
Time until last birth (years) (2–5) 94 (61.8%)
Time until last birth (years) (> 5) 8 (5.3%)
No birth 5 (3.3%)
Comorbid disease
Diabetes mellitus 1 (0.7%)
Thyroid disease 1 (0.7%)
Psychoses 3 (2.0%)
Hypertension 2 (1.3%)
Hyperprolactinemia 21 (13.8%)
Side
Left 81 (53.2%)
Right 59 (38.9%)
Bilateral 12 (7.9%)
Sign and symptoms
Palpable mass with pain 150 (98.7%)
Skin lesion 114 (75%)
Abscess 64 (38.8%)
Fistula 8 (5.3%)
Erythema nodosum 8 (5.3%)
Mass size at onset [43]
 < 1 cm 6 (4.2%)
1–2 cm 40 (26.3%)
3–5 cm 69 (45.6%)
 > 5 cm 36 (23.9%)
Laboratory tests before treatment
C. kroppenstedtii
Positive 36 (23.68%)
White blood cell (WBC) mean [range], *109/L 9.77 ± 3.33 (3.59–17.55)
C-reactive protein (CRP) mean [range], mg/L 11.91 ± 18.91 (1.0–139)
Prolactin (PRL) mean [range], ng/mL 22.70 ± 19.72 (3.5–129.24)
Types of GM
Mass type 74 (48.7%)
Abscess type 66 (43.4%)
Refractory type 12 (7.9%)
Behavior before the onset
Breast trauma 13 (8.6%)
Excitant food 22 (14.47%)
Staying up all night 12 (7.89%)